Orion Oyj (OTCMKTS:ORINY) Short Interest Down 50.0% in March

Orion Oyj (OTCMKTS:ORINY) saw a significant drop in short interest in the month of March. As of March 15th, there was short interest totalling 300 shares, a drop of 50.0% from the February 28th total of 600 shares. Based on an average daily trading volume, of 1,400 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.0% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Separately, Nordea Equity Research lowered shares of Orion Oyj to a “hold” rating in a report on Tuesday, February 4th.

Orion Oyj Price Performance

ORINY opened at $29.35 on Friday. Orion Oyj has a 12-month low of $17.50 and a 12-month high of $30.57. The company has a quick ratio of 1.41, a current ratio of 2.42 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $8.28 billion, a P/E ratio of 23.29 and a beta of 0.25. The stock has a fifty day moving average of $27.98 and a 200-day moving average of $25.68.

Orion Oyj (OTCMKTS:ORINY) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.28 EPS for the quarter. The firm had revenue of $463.41 million during the quarter. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%. Equities analysts forecast that Orion Oyj will post 1.18 EPS for the current fiscal year.

Orion Oyj Increases Dividend

The business also recently disclosed a dividend, which will be paid on Tuesday, April 29th. Shareholders of record on Monday, April 7th will be paid a $0.4478 dividend. The ex-dividend date of this dividend is Monday, April 7th. This is a positive change from Orion Oyj’s previous dividend of $0.24. Orion Oyj’s dividend payout ratio is currently 24.00%.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.